{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAD001%2C+everolimus&page=2", "query": { "intervention": "RAD001, everolimus", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 268, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAD001%2C+everolimus&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAD001%2C+everolimus&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T10:23:48.056Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02143726", "title": "Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Hurthle Cell Thyroid Cancer" ], "interventions": [ { "name": "sorafenib", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-10-09", "completion_date": "2028-08-06", "has_results": true, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 21, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Sioux City, Iowa + 17 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02143726" }, { "nct_id": "NCT00680758", "title": "Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2008-05", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2013-03-08", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 4, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00680758" }, { "nct_id": "NCT00719264", "title": "Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma", "Adenocarcinoma", "Renal Cell", "Nephroid Carcinoma", "Hypernephroid" ], "interventions": [ { "name": "RAD001(everolimus)", "type": "DRUG" }, { "name": "interferon alfa-2a", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2008-11-12", "completion_date": "2013-04-15", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 9, "location_summary": "Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 5 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719264" }, { "nct_id": "NCT02228681", "title": "Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced, Persistent, or Recurrent Endometrial Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Medroxyprogesterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 74, "start_date": "2015-05-21", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 26, "location_summary": "Aurora, Colorado • Miami, Florida • Columbus, Georgia + 21 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Scarborough", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228681" }, { "nct_id": "NCT00529802", "title": "Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2007-09", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-04-25", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 5, "location_summary": "Chicago, Illinois • Peoria, Illinois • Boston, Massachusetts + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00529802" }, { "nct_id": "NCT00323739", "title": "Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2006-05", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2013-07-26", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 12, "location_summary": "Fort Myers, Florida • Gainesville, Florida • Jacksonville, Florida + 9 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323739" }, { "nct_id": "NCT00093639", "title": "Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2004-08", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2013-05-01", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093639" }, { "nct_id": "NCT01283789", "title": "Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Lapatinib and RAD-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 23, "start_date": "2011-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-02-08", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283789" }, { "nct_id": "NCT04485559", "title": "Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent World Health Organization (WHO) Grade II Glioma", "Low-grade Glioma", "High-Grade Glioma (HGG)" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 50, "start_date": "2020-12-09", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04485559" }, { "nct_id": "NCT00436618", "title": "Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Lymphoproliferative Disorder" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 277, "start_date": "2005-08", "completion_date": "2019-10-09", "has_results": true, "last_update_posted_date": "2019-10-22", "last_synced_at": "2026-10-04T10:23:48.056Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436618" } ] }